TABLE 6. Reported cases of notifiable diseases and rates per 100,000, by race, excluding U.S. territories - - United States, 2016 column labels in same order that data fields appears in each record below: Disease American Indian or
Alaska Native, No. American Indian or
Alaska Native, Rate Asian or Pacific
Islander, No. Asian or Pacific
Islander, Rate Black, No. Black, Rate White, No. White, Rate Other Race, No. Race not stated, No. Suppressed *, No. Total tab delimited data: Anthrax — — — — — — — — — — — — Arboviral diseases, Chikungunya virus disease — — 65 0.32 14 0.03 79 0.03 18 71 — 247 Arboviral diseases, Eastern equine encephalitis virus disease, Neuroinvasive S S S S S S S S S S 7 7 Arboviral diseases, Eastern equine encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — — — Arboviral diseases, Jamestown Canyon virus disease, Neuroinvasive S S S S S S S S S S 7 7 Arboviral diseases, Jamestown Canyon virus disease, Non-neuroinvasive S S S S S S S S S S 8 8 Arboviral diseases, La Crosse virus disease, Neuroinvasive — — — — — — 25 0.01 — 6 — 31 Arboviral diseases, La Crosse virus disease, Non-neuroinvasive S S S S S S S S S S 4 4 Arboviral diseases, Powassan virus disease, Neuroinvasive S S S S S S S S S S 21 21 Arboviral diseases, Powassan virus disease, Non-neuroinvasive S S S S S S S S S S 1 1 Arboviral diseases, St. Louis encephalitis virus disease, Neuroinvasive S S S S S S S S S S 7 7 Arboviral diseases, St. Louis encephalitis virus disease, Non-neuroinvasive S S S S S S S S S S 1 1 Arboviral diseases, West Nile virus disease, Neuroinvasive 11 0.24 12 0.06 63 0.14 920 0.36 35 267 — 1,308 Arboviral diseases, West Nile virus disease, Non-neuroinvasive 5 0.11 6 0.03 21 0.05 600 0.24 11 198 — 841 Arboviral diseases, Western equine encephalitis virus disease, Neuroinvasive — — — — — — — — — — — — Arboviral diseases, Western equine encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — — — Babesiosis, Total 7 0.26 44 0.28 41 0.14 1,150 0.63 19 649 — 1,910 Babesiosis, Confirmed 4 0.15 44 0.28 36 0.12 947 0.52 16 538 — 1,585 Babesiosis, Probable 3 0.11 — — 5 0.02 203 0.11 3 111 — 325 Botulism, Total 5 0.11 9 0.04 19 0.04 123 0.05 3 42 — 201 Botulism, Foodborne 3 0.06 2 0.01 12 0.03 9 0.00 — 5 — 31 Botulism, Infant 1 1.29 7 2.80 5 0.73 96 3.24 3 32 — 144 Botulism, Other (wound & unspecified) 1 0.02 — — 2 0.00 18 0.01 — 5 — 26 Brucellosis 2 0.04 4 0.02 3 0.01 85 0.03 15 18 — 127 Campylobacteriosis 479 10.35 1,582 7.72 2,721 6.01 36,747 14.54 3,189 15,402 — 60,120 Chancroid † S S S S S S S S S S 7 7 Chlamydia trachomatis infection † 18,735 404.63 25,594 124.92 452,165 998.00 519,401 205.54 80,410 502,049 — 1,598,354 Cholera S S S S S S S S S S 15 15 Coccidioidomycosis § 167 7.03 332 3.45 431 3.02 3,659 3.49 542 6,698 — 11,829 Cryptosporidiosis, Total 106 2.29 154 0.75 1,283 2.83 9,052 3.58 471 2,387 — 13,453 Cryptosporidiosis, Confirmed 75 1.62 101 0.49 864 1.91 5,663 2.24 306 1,628 — 8,637 Cryptosporidiosis, Probable 31 0.67 53 0.26 419 0.92 3,389 1.34 165 759 — 4,816 Cyclosporiasis 1 0.03 14 0.07 14 0.03 370 0.16 28 110 — 537 Dengue virus infections, Dengue ¶ 1 0.02 161 0.79 60 0.13 396 0.16 57 228 — 903 Dengue virus infections, Dengue-like illness ¶ — — 6 0.03 2 0.00 13 0.01 8 11 — 40 Dengue virus infections, Severe dengue ¶ S S S S S S S S S S 10 10 Diphtheria — — — — — — — — — — — — Ehrlichiosis and Anaplasmosis, Anaplasma phagocytophilum infection 35 0.85 29 0.15 17 0.04 2,686 1.10 36 1,348 — 4,151 Ehrlichiosis and Anaplasmosis, Ehrlichia chaffeensis infection 8 0.19 4 0.02 24 0.05 963 0.40 18 360 — 1,377 Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection S S S S S S S S S S 22 22 Ehrlichiosis and Anaplasmosis, Undetermined ehrlichiosis/anaplasmosis 2 0.05 2 0.01 1 0.00 131 0.05 7 57 — 200 Giardiasis 93 2.60 430 2.45 1,333 3.89 8,049 4.06 728 5,677 — 16,310 Gonorrhea † 6,059 130.86 6,208 30.30 192,977 425.93 144,335 57.12 20,565 98,370 — 468,514 Haemophilus influenzae, invasive disease, All ages, all serotypes 62 1.34 75 0.37 671 1.48 3,183 1.26 144 760 — 4,895 Haemophilus influenzae, invasive disease, Age <5 years, Serotype b 5 1.30 — — 1 0.03 19 0.13 1 4 — 30 Haemophilus influenzae, invasive disease, Age <5 years, Non-b serotype 15 3.89 3 0.23 38 1.11 79 0.53 3 21 — 159 Haemophilus influenzae, invasive disease, Age <5 years, Nontypeable 4 1.04 4 0.31 36 1.06 111 0.75 9 32 — 196 Haemophilus influenzae, invasive disease, Age <5 years, Unknown serotype 7 1.81 9 0.70 31 0.91 96 0.65 15 29 — 187 Hansen's disease — — 12 0.06 5 0.01 36 0.02 1 24 — 78 Hantavirus infection, non-hantavirus pulmonary syndrome S S S S S S S S S S 6 6 Hantavirus pulmonary syndrome 8 0.18 — — — — 19 0.01 1 3 — 31 Hemolytic uremic syndrome post-diarrheal 2 0.04 7 0.04 7 0.02 239 0.10 21 31 — 307 Hepatitis, A, acute ** 3 0.06 301 1.47 141 0.31 1,073 0.42 142 347 — 2,007 Hepatitis, B, acute ** 15 0.33 56 0.27 389 0.87 2,187 0.87 131 440 — 3,218 Hepatitis, B, perinatal infection ** — — 18 3.54 4 0.29 1 0.02 1 8 — 32 Hepatitis, C, acute ** 71 1.77 25 0.13 135 0.31 2,221 0.93 82 408 — 2,942 Human immunodeficiency virus diagnoses 219 4.73 801 3.91 15,632 34.50 9,398 3.72 8,725 — — 34,775 Influenza-associated pediatric mortality 1 0.07 6 0.13 9 0.07 55 0.10 1 10 — 82 Invasive pneumococcal disease, All ages 309 10.75 218 1.84 2,821 7.58 10,403 5.51 457 3,418 — 17,626 Invasive pneumococcal disease, All ages, Confirmed 308 10.71 218 1.84 2,817 7.57 10,388 5.50 457 3,415 — 17,603 Invasive pneumococcal disease, All ages, Probable S S S S S S S S S S 23 23 Invasive pneumococcal disease, Age <5 years 18 0.53 41 0.32 223 0.56 591 0.29 42 227 — 1,142 Invasive pneumococcal disease, Age <5 years, Confirmed 17 5.85 41 4.93 222 7.42 589 4.98 42 226 — 1,137 Invasive pneumococcal disease, Age <5 years, Probable S S S S S S S S S S 5 5 Legionellosis 26 0.56 99 0.48 1,068 2.36 3,891 1.54 242 815 — 6,141 Leptospirosis — — 8 0.05 1 0.00 38 0.02 13 18 — 78 Listeriosis 9 0.19 70 0.34 68 0.15 533 0.21 20 86 — 786 Lyme disease, Total 81 1.75 303 1.55 298 0.66 18,841 7.47 990 15,916 — 36,429 Lyme disease, Confirmed 57 1.23 210 1.07 205 0.45 13,381 5.30 776 11,574 — 26,203 Lyme disease, Probable 24 0.52 93 0.48 93 0.21 5,460 2.16 214 4,342 — 10,226 Malaria 6 0.13 91 0.44 1,052 2.32 248 0.10 67 491 — 1,955 Measles, Total — — 8 0.04 5 0.01 37 0.01 1 34 — 85 Measles, Indigenous — — 2 0.01 2 0.00 32 0.01 — 32 — 68 Measles, Imported S S S S S S S S S S 17 17 Meningococcal disease, All serogroups 9 0.19 12 0.06 60 0.13 229 0.09 15 50 — 375 Meningococcal disease, Serogroups ACWY 7 0.15 4 0.02 22 0.05 70 0.03 6 17 — 126 Meningococcal disease, Serogroup B 1 0.02 1 0.00 15 0.03 58 0.02 2 9 — 86 Meningococcal disease, Other serogroups S S S S S S S S S S 21 21 Meningococcal disease, Unknown serogroup 1 0.02 6 0.03 19 0.04 90 0.04 6 20 — 142 Mumps 20 0.43 2,140 10.45 220 0.49 2,980 1.18 135 874 — 6,369 Novel Influenza A virus infections S S S S S S S S S S 23 23 Pertussis 123 2.66 312 1.52 775 1.71 11,694 4.63 649 4,419 — 17,972 Plague S S S S S S S S S S 4 4 Poliomyelitis, paralytic — — — — — — — — — — — — Poliovirus infection, nonparalytic — — — — — — — — — — — — Psittacosis S S S S S S S S S S 12 12 Q fever, Total 1 0.02 3 0.01 7 0.02 99 0.04 10 44 — 164 Q fever, Acute 1 0.02 2 0.01 6 0.01 83 0.03 8 32 — 132 Q fever, Chronic — — 1 0.00 1 0.00 16 0.01 2 12 — 32 Rabies, Human — — — — — — — — — — — — Rubella S S S S S S S S S S 1 1 Rubella, congenital syndrome S S S S S S S S S S 2 2 Salmonellosis 532 11.49 1,671 8.16 4,401 9.71 34,546 13.67 2,456 10,244 — 53,850 Severe acute respiratory syndrome-associated coronavirus disease — — — — — — — — — — — — Shiga toxin-producing Escherichia coli †† 58 1.25 174 0.85 341 0.75 5,563 2.20 361 1,672 — 8,169 Shigellosis 320 6.91 328 1.60 3,982 8.79 11,547 4.57 1,039 3,881 — 21,097 Smallpox — — — — — — — — — — — — Spotted fever rickettsiosis, Total 42 0.93 16 0.08 112 0.25 2,927 1.16 62 1,110 — 4,269 Spotted fever rickettsiosis, Confirmed 3 0.07 — — 8 0.02 98 0.04 4 41 — 154 Spotted fever rickettsiosis, Probable 39 0.87 16 0.08 104 0.23 2,829 1.12 58 1,069 — 4,115 Streptococcal toxic shock syndrome 1 0.04 6 0.06 43 0.14 194 0.12 14 25 — 283 Syphilis, Total, all stages †,§§ 613 13.24 2,353 11.49 30,820 68.02 41,719 16.51 6,062 6,475 — 88,042 Syphilis, Congenital 12 15.49 26 10.39 261 38.32 281 9.49 14 34 — 628 Syphilis, Primary and secondary † 219 4.73 768 3.75 9,341 20.62 14,103 5.58 1,673 1,710 — 27,814 Tetanus — — 1 0.00 3 0.01 21 0.01 2 7 — 34 Toxic shock syndrome (other than Streptococcal) — — 1 0.01 1 0.00 25 0.01 2 11 — 40 Trichinellosis 5 0.11 8 0.04 2 0.00 8 0.00 — 3 — 26 Tuberculosis 127 2.74 3,212 15.68 2,026 4.47 3,676 1.45 132 99 — 9,272 Tularemia 23 0.50 — — 5 0.01 152 0.06 7 43 — 230 Typhoid fever 4 0.09 185 0.90 31 0.07 61 0.02 29 66 — 376 Vancomycin-intermediate Staphylococcus aureus 1 0.03 2 0.02 23 0.06 61 0.03 6 15 — 108 Vancomycin-resistant Staphylococcus aureus — — — — — — — — — — — — Varicella morbidity 84 2.40 404 2.31 556 1.51 5,583 2.77 375 1,951 — 8,953 Varicella mortality U U U U U U U U U U U U Vibriosis, Total 9 0.20 45 0.22 76 0.17 856 0.34 36 251 — 1,273 Vibriosis, Confirmed 9 0.20 42 0.21 71 0.16 837 0.34 36 246 — 1,241 Vibriosis, Probable — — 3 0.01 5 0.01 19 0.01 — 5 — 32 Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus — — — — — — — — — — — — Viral hemorrhagic fevers, Ebola virus — — — — — — — — — — — — Viral hemorrhagic fevers, Guanarito virus — — — — — — — — — — — — Viral hemorrhagic fevers, Junin virus — — — — — — — — — — — — Viral hemorrhagic fevers, Lassa virus — — — — — — — — — — — — Viral hemorrhagic fevers, Lujo virus — — — — — — — — — — — — Viral hemorrhagic fevers, Machupo virus — — — — — — — — — — — — Viral hemorrhagic fevers, Marburg virus — — — — — — — — — — — — Viral hemorrhagic fevers, Sabia virus — — — — — — — — — — — — Yellow fever S S S S S S S S S S 1 1 Zika virus, Zika virus disease, congenital ¶¶ — — — — 3 0.44 5 0.17 6 16 — 30 Zika virus, Zika virus disease, non-congenital 7 0.15 77 0.38 432 0.95 2,516 1.00 492 1,608 — 5,132 Zika virus, Zika virus infection, congenital ¶¶ — — — — 1 0.15 4 0.14 8 32 — 45 Zika virus, Zika virus infection, non-congenital — — 27 0.13 218 0.48 240 0.09 120 306 — 911 —: No reported cases U: Unavailable S: Suppressed * Condition had <25 cases reported in the year so data were not broken down by race. † Race data were collected using current Office of Management and Budget (OMB) standards for race/ethnicity data and were mapped to bridged race categories. § Reportable in <25 states. ¶ Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM). ** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm. †† Includes Escherichia coli O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped. §§ Includes syphilis of all stages, including cases where stage of syphilis is not stated. ¶¶ Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/zika/reporting/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection. Notes: These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Annual data may differ from previously reported weekly and quarterly data due to revision of information and delayed reporting. The list of national notifiable infectious diseases and conditions for 2016 and their national surveillance case definitions are available at https://wwwn.cdc.gov/nndss/conditions/notifiable/2016/infectious-diseases/, https://wwwn.cdc.gov/nndss/conditions/notifiable/2016/infectious-diseases/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2015 by CSTE for national surveillance, that were implemented in January 2016, including updated surveillance case definitions for acute hepatitis C and chronic hepatitis C virus infections. 2016 data are reported through June 30, 2017. Publication criteria for the finalized 2016 data are available at https://wonder.cdc.gov/nndss/documents/2016_NNDSS_Publication_Criteria.pdf, /nndss/documents/2016_NNDSS_Publication_Criteria.pdf. See also https://wwwn.cdc.gov/nndss/document/guide_to_interpreting_provisional_and_finalized_nndss_data_tables.pdf, Guide to Interpreting Provisional and Finalized NNDSS Data. Population estimates for incidence rates are July 1st, 2016 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for July 1, 2011 - July 1, 2016, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2016), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states as of June 26, 2017 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm, https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2016 mid-year estimates from the U.S. Census Bureau International Data Base accessed on July 24, 2017 at https://www.census.gov/population/international/data/idb/informationGateway.php, https://www.census.gov/population/international/data/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation. NNDSS data displayed in the annual tables are accurate as of October 17, 2017; source data may be updated as additional information is received. Annual tables for 2016 are available on https://wonder.cdc.gov/nndss/nndss_annual_tables_menu.asp, CDC WONDER. Annual summary reports from 1993-2015 are available as published in the https://www.cdc.gov/mmwr/mmwr_nd/index.html, MMWR. Annual summary reports from 1952-1992 are available as published in the MMWR in the https://stacks.cdc.gov/, CDC Stacks. https://wwwn.cdc.gov/nndss/, National Notifiable Diseases Surveillance System Provided by https://wonder.cdc.gov, CDC WONDER